Regeneron Pharmaceuticals gains FDA approval for Lynozyfic drug targeting multiple myeloma, with launch details and executive ...

Cancer-hunting antibodies coupled with a natural compound found in soil microbes proved a powerful combination against an aggressive type of blood cancer, according to a new study from scientists at ...

When ocrelizumab became the first FDA-approved treatment for early forms of multiple sclerosis (MS) in 2017, it offered ...

During early drug development and preclinical development, researchers use in vitro cultured lymphocytes to induce cytokine ...

Lynozyfic (linvoseltamab) has been given accelerated approval by the US regulator for adults with relapsed or refractory ...

HONG KONG, July 3, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") has announced the successful ...

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...

In February 2025 Harbour BioMed announced that the IND application for HBM9378 (SKB378), a TSLP-targeting monoclonal antibody ...

A cancer immunotherapy may slow Parkinson’s disease by blocking the spread of harmful brain proteins, Johns Hopkins researchers found.

Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...

The companies place the partnership’s value at up to $1.5 billion, including an undisclosed up-front payment in the ...